Objective: To explore the clinical effect ofCEF regimen combined with Can Yi capsule in the treatment of livercancer. Methods: From January 2014 to December 2020 our hospital received 118 patients withradical resection of liver cancery after radical surgery and they were divided into the observation group (n=59) and the control group (n=59). The observation group was treated withCEF regimen combined with Can Yi capsule, and the control group was treated withCEF alone. The short-term efficacy, NK and T lymphocyte subsets, quality of life and toxicity were compared between the observation group and the control group. Results: The ORR was 76.27%, and the DCR was 83.05% in the control group; the ORR was 91.53%, and the DCR was 96.61% in the experimental group, the difference was significant (P=0.024，P=0.015). After the intervention, the CD3+, CD4+, CD8+, CD4+/CD8+ and NK indexes in the experimental group were better than those in the control group ( P=0.000, P=0.000, P=0.000, P=0.000, P=0.000). In the physiological condition, psychological status, physical condition and sleep condition score, the experimental group was higher than the control group (P=0.012, P=0.014, P=0.009, P=0.013). In the joint pain, bone marrow suppression, arrhythmia, nausea and vomiting, alopecia, thrombocytopenia, leukopenia and anemia drug toxicity, the experimental group was lower than the control group (P＞0.05). Conclusion: For livercancer patients withradical resection of liver cancery, Can Yi capsule combined withCEF program could not only improve the short-term clinical efficacy, and improve immunity, but also could reduce drug toxicity and improve quality of life.

Dilong Fang, Ying Kong, Yu Ye, Yi Zhang, Qing Gong and Jian-Sheng Wang. Clinical Research of Live Cancer Treated by CEF Regimen Combined with Can Yi Capsule. International Journal of Frontiers in Medicine (2021), Vol. 3, Issue 4: 23-27. https://doi.org/10.25236/IJFM.2021.030404.

[1] Chen Wenyou, Liu Jing, Mao Shunbao, et al. Application of docetaxel + epirubicin in neoadjuvant chemotherapy for livercancer [J]. Shanxi Medical Journal, 2013, 42 (07): 745-746

[2] Liu Chunping, Li Dongxue, Ma Zn. Nursing of livercancer adverse reactions treated with paclitaxel and epirubicin [J]. Journal of clinical rational drug use, 2013, 6 (30): 68-69

[3] Shi bingshuai, Wang Wensheng, Zhao Aiguo, et al. Observation on the short-term efficacy of Nedaplatin Combined with gemcitabine in the treatment of metastatic triple negative livercancer [J]. Journal of practical medicine, 2014, 30 (13): 2154-2156

[4] Qi Jia, Lu Yang, Meng Wei. Intravenous care of epirubicin in the treatment of livercancer [J]. Journal of clinical rational drug use, 2013, 6 (33): 79-80

[5] Shi bingshuai, Wang Xiaolei, Dong Jinlong, et al. Clinicopathological characteristics, treatment and survival after metastasis of triple negative livercancer [J]. Journal of Practical Oncology, 2013, 28 (06): 612-614

[6] Hao Jing, Zhao Pengfei. Retrospective analysis of paclitaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative livercancer [J]. Chinese Journal of clinical pharmacology, 2013, 29 (07): 496-497

[7] Hao Jing, Zhao Pengfei. Clinical study of docetaxel, adriamycin and cyclophosphamide in neoadjuvant treatment of locally advanced livercancer [J]. Chinese Journal of clinical pharmacology, 2014, 10 (04): 303-305

[8] que Jinsong. Effect of pirarubicin and cyclophosphamide combined with docetaxel in neoadjuvant chemotherapy of livercancer [J]. Chinese Journal of clinicians (Electronic Edition), 2015, 12 (21): 3870-3874

[9] Yang Qiumin. Comparison of the efficacy of docetaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative livercancer and non triple negative livercancer [J]. Basic and clinical oncology, 2014, 27 (04): 297-299

[10] Hua Baojin, DU Liang, Tang Rongxin. Clinical evidence of Pingxiao Capsule in the treatment of tumor [J]. Chinese Journal of evidence based medicine, 2013, 13 (08): 1018-1024

[11] Han Xiaorong, Yang Jianmin, Luo Yizhong, et al. Preventive effect and mechanism of Pingxiao Capsule on experimental rat livercancer [J]. Chinese Journal of liverdisease (Electronic Edition), 2013, 7 (05): 329-333

[12] Jin Zhengnan. Clinical observation on the treatment of livercancer withCEF regimen and Pingxiao capsule [J]. Liaoning Journal of traditional Chinese medicine, 2012, 39 (01): 98-99

[13] Yang Qinhui. Study on the clinical efficacy of Pingxiao Capsule in the treatment of livercancer [J]. Gansu science and technology, 2017, 33 (01): 93-94

[14] Weng Jianhua, Xu Suzhen, Hu Meixiao. Study on the application value of epirubicin combined with paclitaxel in the treatment of three yin livercancer [J]. Hebei Medical Journal, 2015, 12 (10): 1468-1470

[15] Sun Fangyi, Wang Hongfang, Shi Jing, et al. Effects of epirubicin based chemotherapy on cardiotoxicity of livercancer patients with diabetes [J]. Chinese Journal of general medicine, 2017, 20 (15): 1898-1902

[16] Zhang Xinting. Application and nursing of epirubicin in the treatment of livercancer patients with heart disease [J]. Qilu Journal of nursing, 2013, 19 (14): 80-81